CANKADO Service
CANKADO Service is recorded as a service provider in 4 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 4 of 4 trials · Latest update first
Adjuvant Dynamic marker - adjusted Personalized Therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk, HR+/HER2- early breast cancer (ADAPTcycle)
Sponsor WSG Women's Cancer Study Group GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing adjuvant Elacestrant with standard endocrine treatment in genomically and/or clinically high-risk ER+/HER2- early breast cancer (ADAPTela)
Sponsor WSG Women's Cancer Study Group GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
An interventional, open-label, phase III study to evaluate the safety, efficacy, and impact on quality of life of capivasertib alongside standard-of-care endocrine treatment in patients with HR+/HER2- advanced breast cancer and progression on prior endocrine-based treatment (CAPIcorn)
Sponsor WSG Women's Cancer Study Group GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
A randomized, controlled, open-label, phase III-trial on Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) intermediate to high risk, HR+/HER2- early breast cancer (ADAPTlate)
Sponsor WSG Women's Cancer Study Group GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for CANKADO Service?
The 2026-10-09 snapshot links CANKADO Service to 4 distinct CTIS trials. Recorded services include Electronic data capture. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for CANKADO Service?
The most frequently recorded therapeutic areas are Solid Tumor Oncology. Recorded phases include Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to CANKADO Service conducted?
The linked trials record locations in 6 countries, including Germany, Spain, Austria, Belgium, Poland. These are trial locations, not confirmed office locations or countries where CANKADO Service delivered services.
What can this page tell me about CANKADO Service's trial experience?
Browse 4 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under CANKADO Service. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- CANKADO Service GmbH